Issue 27

Analyzing the Biggest Biopharma CDMO Trends for 2025

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Five Trends That Will Redefine the CDMO Industry in 2025

The CDMO industry saw significant growth in 2024, as biotech and pharmaceutical companies continued the trend toward outsourcing R&D activities. This surge was evident in the global CDMO market value, which ended the year with a valuation of USD 185 billion. 

Read more here.

FEATURED STORIES

How Europe’s CDMOs are Adapting to Market Dynamics

Read more here.

BioDuro Secures Two EcoVadis Gold Medals for Sustainability Excellence 

Read more here.

ActiGraph Expands Digital Health Portfolio with Biofourmis Life Science Business 

Read more here.

Novo Holdings Completes $16.5 Billion Acquisition of Catalent

Read more here.

Celltrion Expands Global CDMO Operations with Indian Research Hub

Read more here.

Scinai Immunotherapeutics Establishes U.S. CDMO Subsidiary

Read more here.

Lilly's Legal Action to Protect Weight-Loss Drugs

Read more here.

iBio's $29M Deal with AstralBio for Muscle-Preserving Obesity Treatment

Read more here.

Big Pharma Layoffs Surge in 2024 Amid Industry Challenges

Read more here.

Merck's $2 Billion Deal with Hansoh for Oral Obesity Drug

Read more here.

Lifecore Biomedical Partners with Nirsum Labs to Advance Addiction Treatment

Read more here.

Regeneron Acquires Oxular to Expand Ophthalmology Portfolio

Read more here.